Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Pediatr ; 257: 113372, 2023 06.
Artigo em Inglês | MEDLINE | ID: mdl-36870559

RESUMO

Aseptic meningitis is a rare but potentially serious complication of intravenous immunoglobulin treatment. In this case series, meningitic symptoms following intravenous immunoglobulin initiation in patients with multisystem inflammatory syndrome were rare (7/2,086 [0.3%]). However, they required the need for additional therapy and/or readmission.


Assuntos
Imunoglobulinas Intravenosas , Meningite Asséptica , Criança , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Meningite Asséptica/diagnóstico , Meningite Asséptica/tratamento farmacológico , Administração Intravenosa , Progressão da Doença
2.
J Pediatr ; 229: 33-40, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33075369

RESUMO

OBJECTIVE: To describe the similarities and differences in the evaluation and treatment of multisystem inflammatory syndrome in children (MIS-C) at hospitals in the US. STUDY DESIGN: We conducted a cross-sectional survey from June 16 to July 16, 2020, of US children's hospitals regarding protocols for management of patients with MIS-C. Elements included characteristics of the hospital, clinical definition of MIS-C, evaluation, treatment, and follow-up. We summarized key findings and compared results from centers in which >5 patients had been treated vs those in which ≤5 patients had been treated. RESULTS: In all, 40 centers of varying size and experience with MIS-C participated in this protocol survey. Overall, 21 of 40 centers required only 1 day of fever for MIS-C to be considered. In the evaluation of patients, there was often a tiered approach. Intravenous immunoglobulin was the most widely recommended medication to treat MIS-C (98% of centers). Corticosteroids were listed in 93% of protocols primarily for moderate or severe cases. Aspirin was commonly recommended for mild cases, whereas heparin or low molecular weight heparin were to be used primarily in severe cases. In severe cases, anakinra and vasopressors frequently were recommended; 39 of 40 centers recommended follow-up with cardiology. There were similar findings between centers in which >5 patients vs ≤5 patients had been managed. Supplemental materials containing hospital protocols are provided. CONCLUSIONS: There are many similarities yet key differences between hospital protocols for MIS-C. These findings can help healthcare providers learn from others regarding options for managing MIS-C.


Assuntos
COVID-19/terapia , Protocolos Clínicos , Padrões de Prática Médica/estatística & dados numéricos , Síndrome de Resposta Inflamatória Sistêmica/terapia , Anti-Inflamatórios não Esteroides/uso terapêutico , Anticoagulantes/uso terapêutico , Antirreumáticos/uso terapêutico , Aspirina/uso terapêutico , COVID-19/diagnóstico , Criança , Estudos Transversais , Glucocorticoides/uso terapêutico , Heparina/uso terapêutico , Hospitais , Humanos , Imunoglobulinas Intravenosas , Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico , Inquéritos e Questionários , Síndrome de Resposta Inflamatória Sistêmica/diagnóstico , Estados Unidos/epidemiologia , Vasoconstritores/uso terapêutico
4.
J Pediatr ; 201: 176-183.e2, 2018 10.
Artigo em Inglês | MEDLINE | ID: mdl-29891258

RESUMO

OBJECTIVE: To determine the epidemiology of lower extremity deep venous thrombosis (DVT) in critically ill adolescents, which currently is unclear. STUDY DESIGN: We performed a multicenter, prospective, cohort study. Adolescents aged 13-17 years who were admitted to 6 pediatric intensive care units and were anticipated to receive cardiopulmonary support for at least 48 hours were eligible, unless they were admitted with DVT or pulmonary embolism or were receiving or anticipated to receive therapeutic anticoagulation. While patients were in the unit, serial sonograms of the lower extremities were performed, then centrally adjudicated. Bayesian statistics were used to leverage the similarities between adults and adolescents. RESULTS: A total of 88 adolescents were enrolled, from whom 184 lower extremity sonograms were performed. Of these, 9 adolescents developed DVT, with 1 having bilateral DVT. The frequency of DVT was 12.4% (95% credible interval: 6.1%, 20.1%), which ranged from 6.3% to 19.8% with a variability of 41.0% across units. All cases of DVT occurred in adolescents who received invasive mechanical ventilation (frequency: 16.5%; 95% credible interval 8.1%, 26.6%). DVT was associated with femoral central venous catheterization (OR 15.44; 95% credible interval 1.62, 69.05) and severe illness (OR for every 0.1 increase in risk of mortality 3.11; 95% credible interval 1.19, 6.85). DVT appears to be associated with prolonged days on support. CONCLUSIONS: Our findings highlight the similarities and differences in the epidemiology of DVT between adults and adolescents. They support the conduct and inform the design of a trial of pharmacologic prophylaxis in critically ill adolescents.


Assuntos
Estado Terminal , Extremidade Inferior/irrigação sanguínea , Medição de Risco/métodos , Terapia Trombolítica/métodos , Trombose Venosa/epidemiologia , Adolescente , Feminino , Seguimentos , Humanos , Incidência , Unidades de Terapia Intensiva/estatística & dados numéricos , Masculino , Estudos Prospectivos , Fatores de Risco , Estados Unidos/epidemiologia , Trombose Venosa/tratamento farmacológico , Trombose Venosa/etiologia
5.
Pediatr Crit Care Med ; 18(12): 1114-1125, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28926489

RESUMO

OBJECTIVES: Pediatric severe sepsis is a major cause of morbidity and mortality worldwide, and hematopoietic cell transplant patients represent a high-risk population. We assessed the epidemiology of severe sepsis in hematopoietic cell transplant patients, describing patient outcomes compared with children with no history of hematopoietic cell transplant. DESIGN: Secondary analysis of the Sepsis PRevalence, OUtcomes, and Therapies point prevalence study, comparing demographics, sepsis etiology, illness severity, organ dysfunction, and sepsis-related treatments in patients with and without hematopoietic cell transplant. The primary outcome was hospital mortality. Multivariable logistic regression models were used to determine adjusted differences in mortality. SETTING: International; 128 PICUs in 26 countries. PATIENTS: Pediatric patients with severe sepsis prospectively identified over a 1-year period. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: In patients with severe sepsis, 37/567 (6.5%) had a history of hematopoietic cell transplant. Compared with patients without hematopoietic cell transplant, hematopoietic cell transplant patients had significantly higher hospital mortality (68% vs 23%; p < 0.001). Hematopoietic cell transplant patients were more likely to have hospital acquired sepsis and had more preexisting renal and hepatic dysfunction than non-hematopoietic cell transplant patients with severe sepsis. History of hematopoietic cell transplant, renal replacement therapy, admission from inpatient floor, and number of organ dysfunctions at severe sepsis recognition were independently associated with hospital mortality in multivariable analysis; hematopoietic cell transplant conferred the highest odds of mortality (odds ratio, 4.00; 95% CI, 1.78-8.98). In secondary analysis of hematopoietic cell transplant patients compared with other immunocompromised patients with severe sepsis, history of hematopoietic cell transplant remained independently associated with hospital mortality (odds ratio, 3.03; 95% CI, 1.11-8.27). CONCLUSIONS: In an international study of pediatric severe sepsis, history of hematopoietic cell transplant is associated with a four-fold increased odds of hospital mortality after adjustment for potential measured confounders. Hematopoietic cell transplant patients more often originated from within the hospital compared to children with severe sepsis without hematopoietic cell transplant, possibly providing an earlier opportunity for sepsis recognition and intervention in this high-risk population.


Assuntos
Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Sepse/etiologia , Adolescente , Criança , Pré-Escolar , Estudos Transversais , Feminino , Saúde Global , Mortalidade Hospitalar , Humanos , Lactente , Recém-Nascido , Cooperação Internacional , Tempo de Internação/estatística & dados numéricos , Modelos Logísticos , Masculino , Prevalência , Prognóstico , Estudos Prospectivos , Fatores de Risco , Sepse/diagnóstico , Sepse/epidemiologia , Sepse/terapia , Índice de Gravidade de Doença , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA